Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Development of Imaging Endpoints for Clinical Trials in AL and ATTR Amyloidosis: Proceedings of the Amyloidosis Forum.

Development of Imaging Endpoints for Clinical Trials in AL and ATTR Amyloidosis: Proceedings of the Amyloidosis Forum. JACC. Cardiovascular imaging Dorbala, S., Adigun, R., Alexander, K. M., Brambatti, M., Cuddy, S. A., Dispenzieri, A., Dunnmon, P., Emdin, M., Abou Ezzeddine, O. F., Falk, R. H., Fontana, M., Grodin, J. L., Guthrie, S., Jerosch-Herold, M., Hofling, A. A., Hsu, K., Lin, G., Masri, A., Maurer, M. S., Mittmann, C., Prasad, K., Quarta, C. C., Race, J. M., Rajendran, J. G., Ruberg, F. L., Sachdev, V., Sanchorawala, V., Signorovitch, J., Sirac, C., Soman, P., Sorensen, J., Sperry, B. W., Stephens, A. W., Stockbridge, N. L., Vest, J., Wall, J. S., Wechalekar, A., Welsh, C., Lousada, I. 2025

Abstract

Light chain amyloidosis and transthyretin amyloidosis are rare protein misfolding disorders characterized by amyloid deposition in organs, varied clinical manifestations, and poor outcomes. Amyloid fibrils trigger various signaling pathways that initiate cellular, metabolic, structural, and functional changes in the heart and other organs. Imaging modalities have advanced to enable detection of amyloid deposits in involved organs and to assess organ dysfunction, disease stage, prognosis, and treatment response. The Amyloidosis Forum hosted a hybrid meeting to focus on the use of imaging endpoints in clinical trials for systemic immunoglobulin light chain amyloidosis and transthyretin amyloidosis. Stakeholders from academia and industry, together with representatives from multiple regulatory agencies reviewed the use of imaging biomarkers with a focus on cardiac amyloidosis, described applications and limitations of imaging in clinical trials, and discussed qualification of imaging as a surrogate clinical outcome. Survey results provided important patient perspectives. This review summarizes the proceedings of the Amyloidosis Forum.

View details for DOI 10.1016/j.jcmg.2024.11.003

View details for PubMedID 39985507